✦ LIBER ✦

Adjuvant therapy for Breast Cancer in Kyushu

✍ Scribed by Shinichi Wakamatsu; Shoshu Mitsuyama; Kiyoshi Nanba; Reiki Nishimura; Yoshiatsu Sagara; Maki Tanaka; Nobumitsu Tamaki; Toshihiro Koga; Kazuo Tamura; Members of KBC-SG

Publisher: Springer Japan
Year: 2006
Tongue: English
Weight: 27 KB
Volume: 13
Category: Article
ISSN: 1340-6868
DOI: 10.1007/bf02967677

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant therapy for breast cancer

✍ S. Rodenhuis; E. J. T. Rutgers 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Requires sophistication

Breast cancer adjuvant therapy

✍ Paul P. Carbone 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 755 KB

Combined modality trials in early breast cancer have been underway since the 1960s and results are available to indicate varying degrees of success in Stage I and 11. The trials have involved more than 29,000 women in 61 randomized trials. The recommendations can be summarized by stage, estrogen rec

Surgical adjuvant therapy for breast can

Surgical adjuvant therapy for breast cancer

✍ Bernard Fisher 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 834 KB

Adjuvant therapy of breast cancer

✍ Nancy E. Davidson; Martin D. Abeloff 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 605 KB

About 180,000 American women will be diagnosed with early stage breast cancer during 1993. In many of these patients breast cancer is a systemic disease at diagnosis and thus not curable by local treatment alone. The development of optimal forms of systemic adjuvant therapy has been a major area of

Adjuvant systemic therapy for early brea

Adjuvant systemic therapy for early breast cancer

✍ Craig I. Henderson 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 819 KB

Adjuvant systemic therapy for early brea

Adjuvant systemic therapy for early breast cancer

✍ John Crown; Larry Norton 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 890 KB

Sytemic therapy (chemotherapy or hormonal therapy) as an adjuvant to modalities of local control is now an integral part of the management of almost all patients with primary breast cancer metastatic to axillary lymph nodes. In addition, recent data suggest an expanding role for such treatments in p